Evidence map›Paper›PMID 31882498›Full record

Trial reportIn vivo (Athens, Greece)

Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study.

Masaaki Murakawa, Naoto Yamamoto, Yuto Kamioka, Mariko Kamiya, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Yosuke Atsumi, Toru Aoyama, Hiroshi Tamagawa and 4 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The Role of Preoperative Inflammatory Markers in Pancreatectomy: a Norwegian Nationwide Cohort Study.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masaaki MurakawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan m.murakawa@kcch.jp.
Naoto YamamotoDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yuto KamiokaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Mariko KamiyaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Satoshi KobayashiDepartment of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Makoto UenoDepartment of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Manabu MorimotoDepartment of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Yosuke AtsumiDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Toru AoyamaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Hiroshi TamagawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Yasushi RinoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Munetaka MasudaDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Soichiro MorinagaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe C-reactive protein (CRP)-to-serum albumin ratio is associated with a poor prognosis in patients with several cancers. The purpose of this study was to clarify the relationship between the preoperative CRP/Alb ratio and overall survival of pancreatic ductal adenocarcinoma (PDAC) in patients who received radical surgery and S-1 adjuvant chemotherapy. PATIENTS AND

methodsWe included 117 patients who underwent radical surgery with S-1 adjuvant chemotherapy. We constructed receiver operating characteristic curve (ROC curve) of the CRP/Alb ratio to determine the cut-off value. We analyzed the relationship among the CRP/Alb ratio, clinicopathological status, and survival.

resultsThe optimal cut-off value of the CRP/Alb ratio was 0.036. All patients were divided into a high-ratio group (CRP/Alb ratio ≥0.036) and low-ratio group (CRP/Alb ratio <0.036). The 5-year overall survival (OS) rates in the high- and low-ratio groups were 22.5% and 36.4%, respectively (p=0.0089). The 5-year disease-free survival (DFS) rates in the high- and low-ratio groups were 12.5% and 22.1%, respectively (p=0.0097). The univariate and multivariate analyses of the OS showed that the pathological N factor and CRP/Alb ratio were independent factors of the survival. The univariate and multivariate analyses of the RFS showed that the pathological N factor, resection margin, and CRP/Alb ratio were independent factors of the survival.

conclusionThe preoperative CRP/Alb ratio is a strong prognostic factor for PDAC patients with undergo curative resection with S-1 adjuvant chemotherapy.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantCombined Modality TherapyC-Reactive ProteinFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreatectomyPancreatic NeoplasmsBiomarkers, TumorC-Reactive ProteinSerum AlbuminCRP/Alb ratioPancreatic ductal adenocarcinomaprognostic factor

Identifiers

PMID31882498
PMCPMC6984104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.